$Moderna, Inc.(MRNA)$The positive earnings report from Moderna starts with diluted earnings per share of $5.24. That’s well above the $4.55 per share that Wall Street was expecting this quarter — even if it is a drop from the $6.46 reported during the same time last year.
To go along with that, the Covid-19 vaccine maker reported revenue of $4.7 billion for Q2 2022. Yet again, that beats out the $4.07 billion that analysts were looking for during the quarter. It’s also an increase over the $4.4 billion reported during the same period of the year prior.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments